Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CorMedix Inc CRMD

Healthcare
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections... see more

Recent & Breaking News (NDAQ:CRMD)

CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update

GlobeNewswire August 11, 2022

CorMedix Inc. Announces Regulatory and Manufacturing Updates

GlobeNewswire August 8, 2022

CorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11

GlobeNewswire August 1, 2022

CorMedix to Participate at the JMP Securities Life Sciences Conference

GlobeNewswire June 8, 2022

CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 12, 2022

CorMedix Inc. Announces Leadership Updates and Operational Changes

GlobeNewswire May 12, 2022

CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

GlobeNewswire May 3, 2022

CorMedix Inc. Announces Scientific Advisory Board to Support Commercialization and Pipeline Development

GlobeNewswire April 7, 2022

CorMedix Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 4, 2022

CorMedix Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 29, 2022

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

GlobeNewswire March 28, 2022

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29

GlobeNewswire March 22, 2022

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Business Wire March 18, 2022

CorMedix Inc. Announces the Appointment of Chief Executive Officer

GlobeNewswire March 17, 2022

Cormedix Inc. Announces Resubmission of New Drug Application for DefenCath

GlobeNewswire February 28, 2022

CorMedix to Participate in Upcoming January Conferences

GlobeNewswire January 4, 2022

CorMedix Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 9, 2021

CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9

GlobeNewswire November 2, 2021

CorMedix Inc. Announces Abstracts at Upcoming Conferences Showing Patient Outcomes and Economic Burden of CRBSI

GlobeNewswire October 20, 2021

CorMedix Inc. Announces Executive Leadership Changes

GlobeNewswire October 4, 2021